|
|
Other links at Articles > Dermatology |
| 1. |
Rituximab Safe for Systemic Sclerosis, but Efficacy Open to Question
|
|
|
In patients with diffuse cutaneous systemic sclerosis (dcSSc), treatment with rituximab depletes B cells in the peripheral circulation and in skin, with few adverse events. On the other hand, results of a pilot study failed to show any clear beneficial effect on skin disease or other manifestations of the disorder. Reuters Health Information
|
|
|
